<DOC>
	<DOCNO>NCT01512173</DOCNO>
	<brief_summary>There unsatisfied medical need first-line treatment localize uncomplicated proliferate Infantile Hemangioma good benefit/risk profile . Pierre Fabre Dermatologie develop new formulation propranolol ( V0400 GL 01A ) topical gel adapt paediatric use . The objective study evaluate topical propranolol efficacy safety management localize hemangioma .</brief_summary>
	<brief_title>Study Infants With Infantile Hemangioma Compare Propranolol Gel Placebo</brief_title>
	<detailed_description />
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Main one proliferate Infantile Hemangioma present anywhere body except head , neck , hand diaper area , large diameter diameter ≥ 1cm ≤ 5 cm . Main one Infantile Hemangioma large diameter ≥ 1cm medically unstable health status may interfere his/her ability complete study Infantile Hemangioma require , accord Investigator 's judgment , systemic treatment patient previously administer treatment IH surgical and/or medical procedure ( e.g . laser therapy ) perform treat IH</criteria>
	<gender>All</gender>
	<minimum_age>35 Days</minimum_age>
	<maximum_age>150 Days</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Propranolol gel</keyword>
	<keyword>Hemangioma</keyword>
	<keyword>capillary neoplasm</keyword>
	<keyword>vascular tissue</keyword>
	<keyword>neoplasm histologic type</keyword>
	<keyword>neoplasm</keyword>
	<keyword>therapeutic us</keyword>
	<keyword>pharmacologic action</keyword>
	<keyword>adrenergic beta-antagonists</keyword>
	<keyword>adrenergic antagonist</keyword>
	<keyword>adrenergic agent</keyword>
	<keyword>neurotransmitter agent</keyword>
	<keyword>molecular mechanism pharmacological action</keyword>
	<keyword>physiological effect drug</keyword>
</DOC>